Thrombocytopenia: Clinical Trials

443 completed, 190 unknown, 151 recruiting, 90 terminated. 352 Phase 2, 205 Phase 3, 110 Phase 1, 83 Not applicable, 55 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	352	Completed 140, Unknown 70, Recruiting 52, Terminated 42, Not yet recruiting 21, Withdrawn 18, Active not recruiting 9
Phase 3	205	Completed 102, Unknown 29, Terminated 25, Recruiting 22, Active not recruiting 10, Withdrawn 10, Not yet recruiting 7
Phase 1	110	Completed 53, Recruiting 21, Terminated 15, Unknown 8, Not yet recruiting 7, Withdrawn 3, Active not recruiting 2, Enrolling by invitation 1
Not applicable	83	Completed 33, Recruiting 19, Not yet recruiting 10, Unknown 10, Withdrawn 5, Active not recruiting 3, Terminated 3
Phase 4	55	Completed 21, Unknown 19, Recruiting 6, Terminated 5, Withdrawn 3, Not yet recruiting 1
Early Phase 1	17	Completed 5, Recruiting 4, Not yet recruiting 3, Unknown 3, Withdrawn 2

Follow Thrombocytopenia: new trials by email Literature Review of Thrombocytopenia trials Research Report on Thrombocytopenia

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of NM8074 in Patients With aHUS With Evidence of Ongoing Thrombotic Microangiopathy NM8074 - aHUS - Atypical Hemolytic Uremic Syndrome	Phase 2	Not yet recruiting	NovelMed Therapeutics	12	2027-11-01	2026-04-13
A Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary ITP Who Failed Corticosteroids. Ianalumab, Eltrombopag - Primary Immune Thrombocytopenia (ITP)	Phase 2	Not yet recruiting	Novartis Pharmaceuticals	36	2027-02-08	2026-06-25
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias RXIM002 - Immune Thrombocytopenia (ITP)	Phase 1	Not yet recruiting	RiboX Therapeutics Ltd.	27	2027-02-01	2026-10-28
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)	Phase 1 / Phase 2	Not yet recruiting	University Hospital Tuebingen	36	2027-01-01	2026-11-12
A Clinical Study Evaluating the Safety and Preliminary Effectiveness of Induced Pluripotent Stem Cell-derived Platelets in Patients With Thrombocytopenia Caused by Allogeneic Hematopoietic Stem Cell Transplantation iPSC-derived platelets - Thrombocytopenia	Early Phase 1	Not yet recruiting	Ruijin Hospital	9	2026-12-30	2026-10-29
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA Velinotamig specified dose on specified days. - Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)	Phase 1 / Phase 2	Not yet recruiting	Cullinan Therapeutics Inc.	72	2026-12-01	2026-07-31
Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia Luspatercept, Pacritinib - Myelofibrosis	Phase 2	Not yet recruiting	Case Comprehensive Cancer Center	50	2026-12-01	2026-11-13
Sequential Hetrombopag and Recombinant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia Hetrombopag and recombinant human thrombopoietin, Recombinant Human Thrombopoietin - Thrombocytopenia	Phase 2	Not yet recruiting	The First Affiliated Hospital of Zhengzhou University	96	2026-12-01	2026-11-12
Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia Zanubrutinib 80mg/d, High dose dexamethasone, Zanubrutinib 160mg/d - Immune Thrombocytopenia	Phase 2	Not yet recruiting	Peking University People's Hospital	90	2026-12-01	2026-11-12
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias Avatrombopag - Thrombocytopenia	Phase 2	Not yet recruiting	University of Virginia	26	2026-11-01	2026-10-26
Efficacy and Safety of Romiplostim N01 for Injection in Promoting Platelet Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation Romiplostim N01 - Thrombocytopenia, Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2	Not yet recruiting	The First Affiliated Hospital of Henan University of Science and Technology	87	2026-11-01	2026-09-21
Study of Thyroid Dysfunction in Immune Thrombocytopenic Purpura Patients Laboratory tests TSH, FT3, FT4 ,anti thyroglobulin antibodies, Anti -TPO antibodies - Thyroid Dysfunction, Immune Thrombocytopenic Purpura		Not yet recruiting	Sohag University	50	2026-10-25	2026-10-28
TGD001 Treatment in Thrombotic Microangiopathies TGD001 - Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia	Phase 1 / Phase 2	Recruiting	TargED Biopharmaceuticals B.V.	70	2026-10-25	2026-11-12
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias Pacritinib, Selinexor - Myelofibrosis, Post-polycythemia Vera Myelofibrosis	Phase 2	Recruiting	John Mascarenhas	26	2026-10-23	2026-10-27
Neonatal Thrombocytopenia in the NICU Thrombocytopenia, Neonatal Thrombocytopenia		Not yet recruiting	Assiut University	120	2026-10-20	2026-10-20
rhTPO for Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Procedures. rhTPO, Placebo - Thrombocytopenia Associated With Chronic Liver Disease	Phase 3	Recruiting	MIBIO PTE. LTD.	150	2026-10-20	2026-11-06
Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study Hetrombopag, Placebo - Thrombocytopenia, Hepatic Interventional Procedure	Phase 3	Not yet recruiting	Zhongda Hospital	108	2026-10-15	2026-11-09
A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program No Intervention - Thrombotic Thrombocytopenic Purpura (TTP)		Recruiting	Takeda	94	2026-09-24	2026-10-20
Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia Additional blood sample - Thrombocytopenia, Platelet Transfusion		Recruiting	Centre Hospitalier Annecy Genevois	410	2026-09-18	2026-10-22
The Role of interferOn and Complement in SecondAry thRombotic micrioangiOpathy blood draw, urine collection - Thrombotic Microangiopathies	Not applicable	Recruiting	Sofie Dhaese	40	2026-09-15	2026-10-28

Showing 20 of 1015. Sign in to see all of them.

Narrower conditions

Purpura, Thrombocytopenic, Idiopathic (483)  ·  Purpura, Thrombotic Thrombocytopenic (65)  ·  Thrombotic Microangiopathies (49)  ·  Atypical Hemolytic Uremic Syndrome (45)  ·  Anemia (41)  ·  Hematologic Diseases (35)  ·  Hemorrhage (32)  ·  Neutropenia (30)  ·  Purpura, Thrombocytopenic (30)  ·  Myelodysplastic Syndromes (29)  ·  Autoimmune Diseases (26)  ·  Hemolytic-Uremic Syndrome (26)  ·  Anemia, Aplastic (23)  ·  Purpura (23)

Broader conditions

Hemic and Lymphatic Diseases (1015)  ·  Blood Platelet Disorders (1002)  ·  Cytopenia (1002)  ·  Hematologic Diseases (980)  ·  Pathological Conditions, Signs and Symptoms (649)  ·  Pathologic Processes (639)  ·  Thrombotic Microangiopathies (590)  ·  Signs and Symptoms (565)  ·  Blood Coagulation Disorders (558)  ·  Immune System Diseases (557)  ·  Skin Manifestations (550)  ·  Hemorrhage (544)  ·  Purpura (531)  ·  Purpura, Thrombocytopenic (521)

Interventions

eltrombopag (104)  ·  romiplostim (53)  ·  Dexamethasone (49)  ·  Rituximab (47)  ·  avatrombopag (42)  ·  Thrombopoietin (22)  ·  Immunoglobulins, Intravenous (19)  ·  Blood Specimen Collection (18)  ·  Prednisone (17)  ·  eculizumab (15)  ·  hetrombopag (13)  ·  Cyclosporine (12)  ·  Danazol (12)  ·  Platelet Transfusion (12)  ·  Sirolimus (12)

Sponsors

Peking University People's Hospital (54)  ·  Shandong University (44)  ·  Institute of Hematology & Blood Diseases Hospital, China (39)  ·  GlaxoSmithKline (28)  ·  Amgen (26)  ·  Novartis Pharmaceuticals (24)  ·  Alexion Pharmaceuticals, Inc. (21)  ·  Assistance Publique - Hôpitaux de Paris (19)  ·  National Heart, Lung, and Blood Institute (NHLBI) (18)  ·  Assiut University (17)  ·  Eisai Inc. (13)  ·  University Hospital, Bordeaux (13)  ·  Sohag University (12)  ·  Weill Medical College of Cornell University (12)  ·  Takeda (11)

Countries

United States (320)  ·  China (272)  ·  France (144)  ·  Italy (112)  ·  United Kingdom (101)  ·  Germany (100)  ·  Spain (90)  ·  Canada (66)  ·  Poland (61)  ·  Netherlands (54)  ·  Australia (52)  ·  Japan (49)  ·  South Korea (47)  ·  Austria (46)  ·  Belgium (44)

Top investigators

Lei Zhang, MD (18)  ·  Xiao-Hui Zhang, MD (14)  ·  Xiaohui Zhang, MD (10)  ·  Ming Hou, Dr (6)  ·  Ming Hou (5)  ·  Ming Hou, Dr. (5)  ·  Cindy Leissinger, MD (4)

Results publications

PMID 33783815, PMID 19005182, PMID 19846889, PMID 29958797, PMID 40277027, PMID 19671919, PMID 23738544, PMID 24802773, PMID 29419434, PMID 29674506, PMID 34219224, PMID 24254965, PMID 26231455, PMID 26688484, PMID 33995988, PMID 34724566, PMID 12944568, PMID 17077333, PMID 18242413, PMID 20546023, PMID 21533818, PMID 22067384, PMID 22117897, PMID 22409309, PMID 22494019, PMID 23293082, PMID 23470153, PMID 23492914, PMID 24802775, PMID 25566808, PMID 26480931, PMID 27658437, PMID 27734464, PMID 29042367, PMID 29536526, PMID 29778606, PMID 30992268, PMID 32047671, PMID 33031789, PMID 33275766, PMID 33632264, PMID 33881463, PMID 34452956, PMID 34794687, PMID 35030255, PMID 39874521, PMID 10758304, PMID 10786961, PMID 10801186, PMID 10939559

NIH funding

2023 (12), 2018 (7), 2019 (7), 2014 (6), U01HL072268 (5), 2016 (4), 2017 (4), 2025 (3), 2009 (2), 2015 (2), P01HL046925 (2), P30CA016672 (2), 2004 (1), K23HL151882 (1), P01CA015396 (1)